- TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
-
Bang YJ, Takano T, Lin CC, Fasanmade , Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T
- KMID: 2411129
- Cancer Res Treat.
- 2018 Apr;50(2):398-404.
- doi: 10.4143/crt.2017.074
PURPOSE: This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of TAK-264 in Asian patients with advanced gastrointestinal (GI) carcinoma or metastatic or... -
- CITED
-
- Close
- SHARE
-
- Close
